Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.

Inclusion Criteria:

• The patient has a high risk of a cardiovascular event as defined by the European guidelines.
• The patient is statin-naive (i.e. has not used a statin > 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin.
• An LDL-C level is known for the statin-naive patient or for the statin used during visit 1.
• It has been decided to start the patient on CRESTOR 5 mg.
• The patient is prepared to give permission to the coded data being made available to AstraZeneca

Exclusion Criteria:

• The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment.
• Contraindications for treatment with CRESTOR (see 1 B1 text).
• Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia

Clinic